Synapse - Ahmet Dogan

Results (470)

Clinical outcomes with use of radiation therapy and risk of transformation in early-stage follicular lymphoma

Journal Article

Sha, F.; Okwali, M.; Alperovich, A.; Caron, P. C.; Falchi, L.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; Joffe, E.; Khan, N.; more...
Blood Cancer Journal (2022)

Fulltext@MSK | Save

Quantitative off-target detection of Epstein-Barr virus–derived DNA in routine molecular profiling of hematopoietic neoplasms by panel-based hybrid-capture next-generation sequencing

Journal Article

Petrova-Drus, K.; Quesada, A. E.; Bowman, A. S.; Ptashkin, R.; Yao, J.; Arcila, M. E.; Ho, C.; Moung, C.; Regalado, J.; Benayed, R.; more...
Journal of Molecular Diagnostics (2022)

Fulltext@MSK | Save

Clinical characteristics and prognosis of cardiac amyloidosis defined by mass spectrometry-based proteomics in an Australian cohort

Journal Article

Withers, B.; McCaughan, G.; Hayward, C.; Kotlyar, E.; Jabbour, A.; Rainer, S.; De Angelis, E.; Horvath, N.; Milliken, S.; Dogan, A.; more...
Internal Medicine Journal (2022)

Fulltext@MSK | Save

Zanubrutinib, obinutuzumab, and venetoclax in chronic lymphocytic leukemia: Early MRD kinetics define a high-risk patient cohort with delayed bone marrow undetectable MRD and earlier post-treatment MRD recurrence

Meeting Abstract

Soumerai, J. D.; Mato, A. R.; Dogan, A.; Seshan, V.; Joffe, E.; Flaherty, K.; Carter, J.; Hochberg, E. P.; Barnes, J. A.; Hamilton, A.; more...
Blood (2021)

Fulltext@MSK | Save

Interim efficacy analysis of a phase II study demonstrates promising activity of the combination of pembrolizumab (PEM) and entinostat (ENT) in relapsed and refractory (R/R) Hodgkin lymphoma (HL)

Meeting Abstract

Sermer, D. J.; Vardhana, S.; Biggar, E.; Moskowitz, A. J.; Joffe, E.; Khan, N.; Straus, D. J.; Kumar, A.; Zelenetz, A. D.; Horwitz, S. M.; more...
Blood (2021)

Fulltext@MSK | Save

Favorable outcomes of patients with limited-stage ocular adnexal DLBCL treated in the rituximab era: Long-term follow-up of a single center experience

Meeting Abstract

Qualls, D.; Batlevi, C. L.; Caron, P. C.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; Joffe, E.; Khan, N.; Kumar, A.; Matasar, M. J.; more...
Blood (2021)

Fulltext@MSK | Save

Genomic and immune signatures predict sustained MRD negativity in newly diagnosed multiple myeloma patients treated with daratumumab, carfilzomib, lenalidomide, and dexamethasone (D-KRd)

Meeting Abstract

Maura, F.; Boyle, E. M.; Diamond, B.; Blaney, P.; Ghamlouch, H.; Ziccheddu, B.; Wang, Y.; Maclachlan, K. H.; Hoffman, J. E.; Hassoun, H.; more...
Blood (2021)

Fulltext@MSK | Save

The genomic landscape of Waldenström Macroglobulinemia reveals sustained germinal center activity and late-developing copy number aberrations

Meeting Abstract

Maclachlan, K. H.; Bagratuni, T.; Kastritis, E.; Ziccheddu, B.; Lu, S. X.; Yellapantula, V. D.; Famulare, C.; Diamond, B.; Chojnacka, M.; Raj, A.; more...
Blood (2021)

Fulltext@MSK | Save

Phase I first-in-class trial of MCARH109, a G protein coupled receptor class C group 5 member D (GPRC5D) targeted CAR T cell therapy in patients with relapsed or refractory multiple myeloma

Meeting Abstract

Mailankody, S.; Diamonte, C.; Fitzgerald, L.; Kane, P.; Wang, X.; Sikder, D. S.; Senechal, B.; Bermudez, V. P.; Frias, D.; Morgan, J.; more...
Blood (2021)

Fulltext@MSK | Save

Preliminary safety and efficacy from a multicenter, investigator-initiated phase II study in untreated TP53 mutant mantle cell lymphoma with zanubrutinib, obinutuzumab, and venetoclax (BOVen)

Meeting Abstract

Kumar, A.; Soumerai, J. D.; Abramson, J. S.; Batlevi, C. L.; Chadha, P.; Dogan, A.; Falchi, L.; Flaherty, K.; Friedman, C.; Grieve, C.; more...
Blood (2021)

Fulltext@MSK | Save